BMP2K
ENSG00000138756
Target class
Kinase
Chromosome
4
- Chemical probe available
- Yes
- Target name
- BMP2K
- Gene name
- BMP2 inducible kinase
- Gene symbol
- BMP2K
- Protein name
- BMP-2-inducible protein kinase (BIKe) (EC 2.7.11.1)
- DKFZp434K0614
- BIKe
- Gene biotype
- Protein coding
- Gene family
- MicroRNA protein coding host genes
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 21.38
- Tissue specificity (Gini)
- 0.317
- Tissue specificity (tau)
- 0.743
- KEGG gene identifiers
- hsa:55589
- End position
- 78916365
- Start position
- 78776342
- Chromosome
- 4
- Strand
- Forward
- Nucleus .
- Nuclear speckles
Publication evidence
- PubMed 9853615
- Tissue specificity (tau)
- 0.742741
- Expression inequality (Gini)
- 0.316545
Expression in transcripts per million
- Testis
- 21.38
- Nerve - Tibial
- 16.36
- Cells - Cultured fibroblasts
- 16.15
- Cells - EBV-transformed lymphocytes
- 12.45
- Spleen
- 10.67
Expression in transcripts per million
- Testis21.38
- Nerve - Tibial16.36
- Cells - Cultured fibroblasts16.15
- Cells - EBV-transformed lymphocytes12.45
- Spleen10.67
- Lung9.33
- Small Intestine - Terminal Ileum8.41
- Vagina8.38
- Brain - Spinal cord (cervical c-1)8.12
- Esophagus - Mucosa8.12
- Adipose - Subcutaneous7.09
- Thyroid6.93
- Skin - Not Sun Exposed (Suprapubic)6.88
- Whole Blood6.83
- Skin - Sun Exposed (Lower leg)6.79
- Breast - Mammary Tissue6.63
- Artery - Coronary6.36
- Esophagus - Muscularis6.21
- Fallopian Tube6.16
- Esophagus - Gastroesophageal Junction6.09
- Cervix - Ectocervix6.03
- Adipose - Visceral (Omentum)5.59
- Artery - Aorta5.48
- Uterus5.46
- Colon - Transverse5.4
And 29 more, listed on the interactive page.
Cellular components
- GO:0016607
- GO:0005515
- GO:0106310
Related records
Trials (170)
- "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
- A Moderate to Severe Rheumatoid Arthritis Study
- A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
- A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas
- A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
- A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients
- A Relative Bioavailability and Food Effect Study of New Formulations
- A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
- A Study in Moderate to Severe Rheumatoid Arthritis
- A Study in Moderate to Severe Rheumatoid Arthritis Participants
- A Study in Participants With Moderate to Severe Rheumatoid Arthritis
- A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
- A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
- A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
- A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata